文献速递预防保健、筛查与疫苗慢病管理

乙型肝炎:筛查、预防、诊断与治疗

Hepatitis B: Screening, Prevention, Diagnosis, and Treatment.
PubMed 文献 · Am Fam Physician · 2019-01-01

乙型肝炎由HBV引起,可致急性和慢性肝感染。建议孕妇首次产检时筛查,高危青少年和成人也应筛查;推荐新生儿出生24小时内接种疫苗。急性乙肝无抗病毒治疗有效证据,慢性乙肝需个体化治疗以降低肝硬化和肝癌风险。

要点

  • 孕妇首次产检应筛查乙肝,高危青少年和成人也建议筛查。
  • 体重≥2000g且医学稳定的新生儿出生24小时内接种乙肝疫苗。
  • 慢性乙肝定义为HBsAg持续超过6个月,需评估肝病分期指导治疗。

核心结论

  • 乙肝筛查应覆盖孕妇和高危人群,疫苗接种是重要预防手段。
  • 急性乙肝无抗病毒治疗有效的证据,慢性乙肝需个体化治疗。
  • 慢性乙肝患者有肝细胞癌和肝硬化风险,充分治疗可降低 morbidity 和 mortality。

研究设计与样本

  • 本文为综述,汇总乙肝筛查、预防、诊断和治疗的相关证据与推荐。

主要发现

  • 急性乙肝定义为症状离散发作、黄疸或血清ALT升高,且HBsAg和HBcAg检测阳性。
  • 慢性乙肝定义为HBsAg持续超过6个月,患者有肝细胞癌和肝硬化风险。
  • 免疫学治愈定义为HBsAg丢失且HBV DNA持续抑制,当前药物可实现。

关键数值与推荐

  • 孕妇首次产检时推荐筛查乙肝。
  • 高危青少年和成人推荐筛查乙肝。
  • 医学稳定且体重≥2000g的新生儿出生24小时内推荐接种乙肝疫苗。
  • 未接种的婴儿、儿童及要求保护的未接种成人或感染风险增加者推荐接种乙肝疫苗。
  • 聚乙二醇干扰素α-2a、恩替卡韦和替诺福韦推荐为慢性乙肝一线治疗。

临床怎么用

  • 全科医生应识别高危人群进行乙肝筛查,并推动新生儿及时接种疫苗。
  • 对慢性乙肝患者评估肝病分期(炎症、纤维化),以指导治疗和肝癌监测。
  • 慢性乙肝治疗应基于临床和实验室特征及肝硬化和肝癌风险个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatitis B virus (HBV) is a partly double-stranded DNA virus that causes acute and chronic liver infection. Screening for hepatitis B is recommended in pregnant women at their first prenatal visit and in adolescents and adults at high risk of chronic infection. Hepatitis B vaccination is recommended for medically stable infants weighing 2,000 g or more within 24 hours of birth, unvaccinated infants and children, and unvaccinated adults requesting protection from hepatitis B or who are at increased risk of infection. Acute hepatitis B is defined as the discrete onset of symptoms, the presence of jaundice or elevated serum alanine transaminase levels, and test results showing hepatitis B surface antigen and hepatitis B core antigen. There is no evidence that antiviral treatment is effective for acute hepatitis B. Chronic hepatitis B is defined as the persistence of hepatitis B surface antigen for more than six months. Individuals with chronic hepatitis B are at risk of hepatocellular carcinoma and cirrhosis, but morbidity and mortality are reduced with adequate treatment. Determining the stage of liver disease (e.g., evidence of inflammation, fibrosis) is important to guide therapeutic decisions and the need for surveillance for hepatocellular carcinoma. Treatment should be individualized based on clinical and laboratory characteristics and the risks of developing cirrhosis and hepatocellular carcinoma. Immunologic cure, defined as the loss of hepatitis B surface antigen with sustained HBV DNA suppression, is attainable with current drug therapies that suppress HBV DNA replication and improve liver inflammation and fibrosis. Pegylated interferon alfa-2a, entecavir, and tenofovir are recommended as first-line treatment options for chronic hepatitis B.

来源:Am Fam Physician,查看原文。版权归原作者所有。

引用

  1. Wilkins T, Sams R, Carpenter M, et al. Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. Am Fam Physician. 2019. PMID: 30811163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。